Company: GNMSF
Filing Date: 2025-12-12
Form Type: SC TO-T/A
Source: 0001193125-25-316835
Chunk: 2

Company: GENMAB A/S
Filing Date: 2025-12-12
Form: SC TO-T/A
Chunk 2
---
 the Offer to Purchase. Except as otherwise set forth in this Amendment
No. 3, the information set forth in the Schedule TO remains unchanged and is incorporated herein by reference to the extent relevant to the items in this Amendment No. 3. This Amendment No. 3 should be read together with the Schedule
TO.

Items 1 through 9; Item 11.

The
Offer to Purchase and Items 1 (Summary Term Sheet) through 9 (Persons/Assets Retained, Employed, Compensated or Used) and Item 11 (Additional Information) of the Schedule TO, to the extent such Items incorporate by
reference the information contained in the Offer to Purchase, are hereby amended and supplemented by adding the following paragraphs thereto:

At 5:00 p.m. New York City time on December 11, 2025, the Offer and withdrawal rights expired as scheduled. The Depositary
has advised Genmab and Purchaser that, as of the Expiration Time, a total of 71,463,077 Common Shares had been validly tendered pursuant to the Offer and not properly withdrawn. For purposes of the Minimum Condition, the aggregate number of Common
Shares validly tendered pursuant to the Offer and not properly withdrawn represents approximately 94.2% of the total issued and outstanding share capital of Merus (calculated in accordance with the Transaction Agreement) as of the Expiration Time.
As a result, the number of Common Shares validly tendered pursuant to the Offer and not properly withdrawn as of the Expiration Time satisfied the Minimum Condition. All other Offer Conditions having been satisfied or waived, and effective at 12:01
a.m. New York City time on December 12, 2025, Purchaser has accepted for payment, and expects to promptly pay for, all Common Shares validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time.

Pursuant to the Transaction Agreement and in accordance with Rule 14d-11 promulgated
under the Exchange Act, Purchaser has commenced the Subsequent Offering Period, which will expire at 5:00 p.m. New York City time on December 29, 2025. All Common Shares validly tendered during the Subsequent Offering Period will be immediately
accepted and promptly paid for by Purchaser, and tendering Merus Shareholders will receive the same Offer Consideration of $97.00 per Common Share, less any applicable withholding taxes and without interest,